Moonlake Immunotherapeutics · NASDAQ:MLTX
Moonlake Immunotherapeutics — Helix Acquisition — SPAC Merger (October 2021)
33 slides from Moonlake Immunotherapeutics's SPAC merger presentation, Oct 4, 2021
Slide 1: Proposed deal with Helix Acquisition Corp.
1 © 2021 | Confidential and Proprietary MoonLake Immunotherapeutics AG Proposed deal with Helix Acquisition Corp. STRICTLY CONFIDENTIAL September 2021 www.moonlaketx.com
Slide 2: Disclaimer (1/2)
2 Disclaimer (1/2) © 2021 | Confidential and Proprietary | MoonLake Immunotherapeutics AG Important Information for Investors This confidential presentation (“Presentation”) is for informational purposes only and is being provided to interested parties solely in their capacity as potential investors
Slide 3: Disclaimer (2/2)
3 Disclaimer (2/2) © 2021 | Confidential and Proprietary | MoonLake Immunotherapeutics AG Trademarks This Presentation may contain trademarks, service marks, trade names and copyrights of other companies, which are the property of their respective owners . Solely for convenience, some of the tradema
Slide 4: MoonLake Executive Team
4 MoonLake Executive Team © 2021 | Confidential and Proprietary | MoonLake Immunotherapeutics AG K. Reich (CSO) MD, PhD ~100 years of combined experience in Immunology – across R&D, Clinical, Regulatory, Launch, Commercial & BD • 30+ years experience as a global clinical leader in dermatology & immu
Slide 5: Our focus: Unlocking the potential of the innovative nanobody Sonelokimab
5 Our focus: Unlocking the potential of the innovative nanobody Sonelokimab © 2021 | Confidential and Proprietary | MoonLake Immunotherapeutics AG □ We are developing Sonelokimab (SLK), a nanobody with potential to change Immunology practice A tri - specific IL17A/F nanobody with the potential to be
Slide 6: The HELIX + MoonLake combination creates significant opportunity
6 The HELIX + MoonLake combination creates significant opportunity © 2021 | Confidential and Proprietary | MoonLake Immunotherapeutics AG + HELIX ACQUISITION CORPORATION ▪ Combination with HELIX accelerates MoonLake’s ambitions and Phase II development programs for SLK ▪ HELIX investors access an as
Slide 7: A distinctive molecule
7 A distinctive molecule
Slide 8: SLK is a tri-specific anti-IL-17A/F nanobody
8 SLK is a tri - specific anti - IL - 17A/F nanobody © 2021 | Confidential and Proprietary | MoonLake Immunotherapeutics AG SOURCE: Merck KGaA, Darmstadt, Germany, MoonLake V HH C H 2 Presentation Phase 0/1: Frozen liquid solution containing 60 mg/mL of API Phase 2: Freeze dried formulation with two
Slide 9: SLK is the only nanobody among IL-17, IL-23 & TNF inhibitors
9 SLK is the only nanobody among IL - 17, IL - 23 & TNF inhibitors © 2021 | Confidential and Proprietary | MoonLake Immunotherapeutics AG SOURCE: MoonLake Team IL - 17A – IL - 17A IL - 17F IL - 17F IL - 17RA IL - 17RA IL - 17RC B i m eki z u mab B r o IL - SLK Secukinumab Bimekizumab Ixekizumab The
Slide 10: SLK and BKZ achieve higher PASI75 scores at week 4
10 © 2021 | Confidential and Proprietary | MoonLake Immunotherapeutics AG SOURCE: Reich K, et al. N Engl J Med. 2021 Apr 23. doi: 10.1056/NEJMoa2102383 , MoonLake Therapeutic difference 13% W eeks W eeks SLK and BKZ achieve higher PASI75 scores at week 4 than other leading molecules BKZ illustrates
Slide 11: Potential for higher efficacy of SLK versus the IL-17 market leader
11 Potential for higher efficacy of SLK versus the IL - 17 market leader © 2021 | Confidential and Proprietary | MoonLake Immunotherapeutics AG PASI: Psoriasis Area and Severity Index SOURCE: Merck KGaA, Darmstadt, Germany, MoonLake 22 29 35 49 53 59 57 0 2 5 5 9 21 34 34 37 34 60 55 50 45 40 35 30
Slide 12: SLK has a differentiated safety profile to date
12 SLK has a differentiated safety profile to date © 2021 | Confidential and Proprietary | MoonLake Immunotherapeutics AG SOURCE: MoonLake Team, The Lancet • Favorable overall safety profile including infection rate similar to Secukinumab • Candida rate similar to those previously observed with IL -
Slide 13: Expanding the potential
1 3 Expanding the potential
Slide 14: SLK to unlock value in A/F Inflammatory Diseases (AFID)
14 SLK to unlock value in “A/F Inflammatory Diseases (AFID)” © 2021 | Confidential and Proprietary | MoonLake Immunotherapeutics AG Rheumatology (Oxford). 2013; Tekin et al. J Rheumatol. 2019; Alinaghi et al. J Am Acad Dermatol. 2019; Reich et al. Br J Dermatol. 2009; Gelfand et al. Arch Dermatol. 2
Slide 15: 1. MoonLake Upside potential
1 5 1. MoonLake Upside potential
Slide 16: SLK has potential in significantly growing $40bn+ market
16 SLK has potential in significantly growing $40bn+ market © 2021 | Confidential and Proprietary | MoonLake Immunotherapeutics AG SOURCE: IQVIA, Clarivate’s Market Forecast Assumptions file for Psoriasis – May 2021 (2019 - 2029, part of Disease Landscape & Forecast) DRG's Market Forecast Assumption
Slide 17: 2. AFID Unmet needs beyond PsO
1 7 2. AFID Unmet needs beyond PsO
Slide 18: IL-17A/F inhibition elevates Psoriatic Arthritis treatment goal to ACR 50
18 IL - 17A/F inhibition is the first mechanism to elevate Psoriatic Arthritis (PsA) treatment goal to ACR 50 – potential to outperform Humira © 2021 | Confidential and Proprietary | MoonLake Immunotherapeutics AG a Placebo data for BE ACTIVE are from Week 12 1 Mease PJ, et al. Arthritis Rheum 2005;
Slide 19: IL-17A/F inhibition elevates Ankylosing Spondylitis treatment goal to ASAS40
19 IL - 17A/F inhibition is the first mechanism to elevate Ankylosing Spondylitis (AS, r - axSpA) treatment goal to ASAS40, where others have failed © 2021 | Confidential and Proprietary | MoonLake Immunotherapeutics AG ASAS40, Assessment of SpondyloArthritis international Society 40 response [defin
Slide 20: IL-17A/F inhibition elevates Hidradenitis suppurativa treatment goal to HiSCR 75
20 IL - 17A/F inhibition is the first mechanism to elevate Hidradenitis suppurativa (HS) treatment goal to HiSCR 75 © 2021 | Confidential and Proprietary | MoonLake Immunotherapeutics AG HiSCR75, at least 75% reduction in Hidradenitis Suppurativa Clinical response (reduction in total abscess and nod
Slide 21: BKZ inhibition of IL17 A/F across AFID underscores SLK opportunity
21 BKZ inhibition of IL17 A/F across AFID underscores SLK opportunity © 2021 | Confidential and Proprietary | MoonLake Immunotherapeutics AG is phase 3; in AS, IXE and ADA is from direct comparator trials; in HS, all data is from one phase 2 study) 1 Ritchlin CT, et al. Lancet 2020;395:427 – 40; 2 M
Slide 22: 3. SLK nanobody Differentiation potential
2 2 3. SLK nanobody Differentiation potential
Slide 23: Penetration: Tri-specific SLK has potential for differential enrichment at joints
23 Penetration: Tri - specific SLK has potential for differential enrichment at joints © 2021 | Confidential and Proprietary | MoonLake Immunotherapeutics AG SOURCE: MoonLake and selected publications Albumin and albumin - bound drugs enrich at sites of joint inflammation (murine RA model) 3h after
Slide 24: Penetration: Arthritic joint assessment indicates SLK efficacy in deep tissue
24 Penetration: Arthritic joint assessment indicates SLK efficacy in deep tissue 1 Assessed joints for the determination of Arthritis score. The scored joints are indicated (red circles) for the large joints (top panel), forelimb joints (middle panel) and hindlimb joints (bottom panel). DIP, distal
Slide 25: Safety: SLK clinical data supports a superior safety profile vs BKZ
25 Safety: SLK clinical data supports a superior safety profile vs BKZ © 2021 | Confidential and Proprietary | MoonLake Immunotherapeutics AG IMPORTANT NOTES: 1 For SLK: “initial period “is 0 - 12 weeks and “1 yr” is 12 - 52 weeks; 2 Main PsO dose is 120mg with normal load (Wks 0, 2, 4, 8); 3 All do
Slide 26: Safety: Skin levels of IL-17A and F need differential control
26 Safety: Skin levels of IL - 17A and F in PsO patients need to be differentially controlled for optimal benefit - risk profile © 2021 | Confidential and Proprietary | MoonLake Immunotherapeutics AG Baseline IL - 17A and IL - 17F levels in the dermis (dISF) of healthy volunteers (HV, circles) and l
Slide 27: Safety: Superior SLK safety could be due to modulated dimer inhibition
27 Safety: Superior SLK safety could be due to its modulated dimer inhibition © 2021 | Confidential and Proprietary | MoonLake Immunotherapeutics AG 1 HT - 1080, human fibrosarcoma cell line; cytokine measured in the presence of human serum albumin: nd, not done SOURCE: Merck KGaA, Darmstadt, German
Slide 28: MoonLake value creation
2 8 MoonLake value creation
Slide 29: SLK has a proven benefit-risk profile
2 9 29 © 2021 | Confidential and Proprietary | MoonLake Immunotherapeutics AG SLK has a proven benefit - risk profile Psoriasis (incl. vs BKZ) SLK is a distinctive molecule with enhanced enrichment in deep skin & joints and binding of targets with better - than - mAb affinity and specificity – a pot
Slide 30: Initiating multiple phase II studies in A/F Inflammatory Diseases in 2022
30 Development 1 17 O pe r ations 49 Initiating multiple phase II studies in A/F Inflammatory Diseases in 2022 © 2021 | Confidential and Proprietary | MoonLake Immunotherapeutics AG SOURCE: MoonLake Team (July 2021) 2021 2024 2025 2022 2023 Start - up PsA Phase II PE: 16/48wk 240 pts HS Phase II PE:
Slide 31: Transaction overview and summary
Transaction overview and summary © 202 1 | Con fid en tial an d P ropr iet ar y | M oonLa ke I m mu no t herapeu ti c s AG 31 © 2021 | Confidential and Proprietary | MoonLake Immunotherapeutics AG 31 Healthy news flow High - potential Biotech ▪ Four multi - billion dollar indications ▪ World - class
Slide 32: 32
32
Slide 33: Additional supporting documents: Literature of relevance
33 Additional supporting documents Literature of relevance Risankizumab Blauvelt A, et al. JAMA Dermatol. 2020 Apr 8. [Epub ahead of print] (PsO randomized withdrawal); Reich K, et al. Lancet. 2019 Aug 17;394(10198):576 - 586 (PsO vs. ADA) Gordon KB, et al. Lancet. 2018 Aug 25;392(10148):650 - 661 (